Nanotech hep B vaccine could revolutionize therapy

Scientists at the University of Michigan are moving closer to human trials of a new nanoemulsion hepatitis B vaccine that could revolutionize therapy in the third world. The nanoemulsion approach avoids the work needed to keep syringes sterile, refrigeration and the repeated jabs required by current vaccines. The first human trial could launch in a year.

"Our results indicate needle-free nasal immunization, using a combination of nanoemulsion and hepatitis B antigen, could be a safe and effective hepatitis B vaccine, and also provide an alternative booster method for existing vaccines," said Dr. James Baker Jr., the study's senior author.

- check out the release
- read the UPI report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.